XML 124 R108.htm IDEA: XBRL DOCUMENT
v3.21.2

License Agreements (Details) - USD ($) $ in Millions |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Apr. 12, 2021 | Apr. 30, 2020 | Oct. 31, 2018 | Oct. 31, 2017 | Feb. 29, 2016 | Jun. 30, 2021
License Agreement 2014 | Maximum | Neos Therapeutics, Inc. |  |  |  |  |  |
Lump sum non-refundable license fee |  |  |  |  | $ 1.0 |
License Agreement 2017 | Maximum | Neos Therapeutics, Inc. |  |  |  |  |  |
Lump sum non-refundable license fee |  |  |  | $ 1.0 |  |
License Agreement 2014 and 2017 | Neos Therapeutics, Inc. |  |  |  |  |  |
License agreement term |  | 10 years |  |  |  |
License fee |  | $ 0.3 |  |  |  |
Patent prosecution fees |  | 0.1 |  |  |  |
NeuRx License, Royalty Bearing License Agreement |  |  |  |  |  |
Payments for license agreement |  |  | $ 0.2 |  |  | $ 0.2
Payments for contingent consideration on license agreement |  | $ 0.3 |  |  |  |
In-process R&D | Rumpus |  |  |  |  |  |
Contingent consideration | $ 67.5 |  |  |  |  |
Cash transferred | 1.5 |  |  |  |  |
Payment of aggregated fees | 0.6 |  |  |  |  |
In-process R&D | Rumpus | Maximum |  |  |  |  |  |
Contingent consideration | $ 67.5 |  |  |  |  |

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References No definition available. + Details
Name: | aytu_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of consideration transferred for transaction cost incurred in asset acquisition. + References No definition available. + Details
Name: | aytu_AssetAcquisitionConsiderationTransferredForTransactionCost
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the information pertaining to for contingent consideration arrangements recognized in connection with an asset purchase, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References No definition available. + Details
Name: | aytu_AssetPurchaseContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period of license agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | aytu_LicenseAgreementTerm
Namespace Prefix: | aytu_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represent the information pertaining to license fee. + References No definition available. + Details
Name: | aytu_LicenseFee
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents lump sum non-refundable license fee. + References No definition available. + Details
Name: | aytu_LumpSumNonrefundableLicenseFee
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the information pertaining to patent prosecution fees. + References No definition available. + Details
Name: | aytu_PatentProsecutionFees
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the contingent consideration on the license agreement. + References No definition available. + Details
Name: | aytu_PaymentsForContingentConsiderationOnLicenseAgreement
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cash paid for the license agreement. + References No definition available. + Details
Name: | aytu_PaymentsForLicenseAgreement
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aytu_LicenseAgreement2014Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=aytu_NeosTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aytu_LicenseAgreement2017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aytu_LicenseAgreement2014And2017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aytu_NeuRxLicenseRoyaltyBearingLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | aytu_AssetAcquisitionAxis=aytu_RumpusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |